Forty-four evaluable, previously untreated patients with small cell lung cancer were treated with two courses of induction chemotherapy consisting of POCC. Subsequently, all limited-disease patients and extensive-disease patients in CR received 4,000 to 5,000 cGy irradiation over 4 to 5 weeks (or the equivalent) to the primary tumor, mediastinum and supraclavicular areas and 3,000 cGy prophylactic cranial irradiation during 2 weeks. All patients received maintenance chemotherapy for a full year after CR or until disease progression. Eleven continued POCC while 33 received vinblastine, cyclophosphamide, and either adriamycin or methotrexate on an alternating schedule (VCMA). For the 20 limited-disease patients, the CR rate was 70% and the PR rate was 20%. Median survival was 22 months, local control was 62%, 2-year DFS was 35% and 3-year DFS was 20%. Of the 24 extensive-disease patients only 21% achieved CR and 54% achieved PR. Median survival was only 8 months and there were no disease-free survivors at 2 years. Toxicity was moderate with nausea and vomiting in all patients, and there were two deaths from myelosuppression in the group that received POCC maintenance therapy; there were no drug-related deaths in the VCMA group. Since these results are similar to those obtained with simpler regimes, we cannot recommend our regimen for the treatment of small cell lung cancer. The optimal treatment for this disease has yet to be elucidated.

A retrospective study of all cases of pure testicular seminoma treated at the Hadassah University Hospital in Jerusalem from 1978 through 1986 was conducted. Of the 22 patients, 15 (70%) presented in Stage I, 4 (18%) in Stage II, 2 (9%) in Stage III and 1 (4%) in Stage IV. The results of treatment were evaluable for 20 of these patients. After a median follow-up of 4 years, only the patient with Stage IV disease died of disseminated seminoma. The remaining 19 patients are all alive and disease free, including 3 after radiotherapy for recurrent disease. Elevated beta-human chorionic gonadotropin levels before treatment did not predict an unfavorable outcome. Our excellent results are similar to those obtained at larger treatment centers.